MacroGenics, Inc.

MGNXNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
3.91 USD
↘ 0.34 (8.00%)AT CLOSE (11:59 AM EDT)
3.91
↗ 0.00 (0.08%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
3.91
↗ 0.00 (0.08%)
🔴Market: CLOSED
Open?$4.27
High?$4.29
Low?$3.87
Prev. Close?$4.25
Volume?560.1K
Avg. Volume?1.2M
VWAP?$4.00
Rel. Volume?0.47x
Bid / Ask
Bid?$3.85 × 100
Ask?$3.94 × 100
Spread?$0.09
Midpoint?$3.90
Valuation & Ratios
Market Cap?248.5M
Shares Out?63.6M
Float?61.5M
Float %?97.3%
P/E Ratio?N/A
P/B Ratio?11.72
EPS?-$1.11
Dividend?0.00%
Ex-Dividend?N/A

MacroGenics, Inc. (MGNX) is currently trading at $3.91. MGNX shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. MGNX is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
293
Market Cap
248.5M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.macrogenics.com
Listed
2013-10-10
Address
9704 MEDICAL CENTER DRIVE
Rockville, MD 20850
Phone: 301-251-5172
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
50
Short Sent.?
56
Piotroski F-Score?3/9Weak
Altman Z-Score?-7.24Distress
Confidence?55%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?7.93%Elevated
Short Interest?4.9M
Days to Cover?2.5
Free Float61.5M
Avg Daily Volume2.0M
Settlement Date2026-05-15
Financial Health
Current Ratio?1.90Adequate
Quick Ratio?1.80Adequate
Cash Ratio?0.69Adequate
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
17
11.72HIGH▾
P/S?
Peers
100
S&P
77
1.58CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.2CHEAP▾
EV/Sales?
Peers
100
S&P
89
1.16CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-332.2%WEAK▾
ROA?
S&P
3
-32.3%WEAK▾
Cash Flow & Enterprise
FCF?$-71690000
Enterprise Value?$182.0M
Fundamentals ratios updated end of day
MarketsMoversWatchlist